Skip to content

Design, synthesis, mechanistic evaluation, and in silico study of pyrimidine-coumarin hybrids as promising anticancer agents.

Sep 2026 · Bioorganic chemistry (Print) · Vol 183, pp. 110579 · 0 citations · 32 references
Medicine

Abstract

Breast and lung cancers remain among the leading causes of cancer-related mortality worldwide, highlighting the urgent need for the development of effective targeted therapeutics. In this study, a series of novel pyrimidine-coumarin hybrid derivatives were rationally designed, synthesized, and biologically evaluated for their antiproliferative activity against MDA-MB-231 breast cancer and A549 lung cancer cell lines. The synthesized compounds were initially screened using the MTT assay, followed by detailed mechanistic and computational investigations of the most active derivatives. Among the synthesized compounds, 8b exhibited the highest antiproliferative activity, with IC₅₀ values of 23.2 μM against MDA-MB-231 and 69.19 μM against A549 cells, while 8g displayed IC₅₀ values of 32.41 μM and 113.3 μM, respectively. Mechanistic studies revealed that compounds 8b and 8g significantly downregulated epidermal growth factor receptor (EGFR) protein, induced apoptosis, and triggered G2/M-phase cell-cycle arrest in MDA-MB-231 cells, suggesting that their antiproliferative effects are mediated through EGFR protein expression. Computational studies, including molecular docking, molecular dynamics simulations, MM/GBSA binding free-energy calculations, density functional theory (DFT) analysis, and ADMET prediction, provided complementary structural, energetic, electronic, pharmacokinetic, and drug-likeness insights into the observed biological activity by demonstrating stable binding of the lead compounds within the EGFR active site, together with favorable electronic, pharmacokinetic, and drug-likeness profiles. Collectively, these results identify pyrimidine-coumarin hybrids, particularly compounds 8b and 8g, as promising lead scaffolds for the development of EGFR-targeted anticancer agents against breast and lung cancers.

View source

Similar papers

Sep 2026

Design, synthesis, and biological evaluation of novel dihydropyrimidinone imines as potent anticancer agents targeting AKT to induce cell cycle arrest and apoptosis in breast Cancer cells.

Findings indicate that compound 10 exerts efficient antineoplastic impact associated with the downregulation of the RAS/PI3K/AKT/GSK-3β pathway proteins.

Maria N. Gerges, Ahmed A. Noser, Eman G. Ibrahim et al. · 0 citations
Open access Sep 2026

Design, synthesis, and preliminary anticancer evaluation of diphenylpropan-1-one derivatives: in vitro, in vivo and in silico studies

A series of diphenylpropan-1-one (DPP) derivatives (4a–4i), rationally designed around a chalcone framework and synthesized via a three-step reaction sequence demonstrated encouraging preliminary anticancer potential and may serve as promising lead molecules for future investigations.

A. Najmi, M. S. Alam, W. Ahsan et al. · 0 citations
Oct 2026

Design, Synthesis, Characterization and In-vitro Evaluation of Novel Isatin derivatives as Anti-lung Cancer agents inhibiting CDK2 Enzyme

Lung cancer is one of the most prevalent and lethal malignancies globally, responsible for more than 1.3 million deaths each year. Cyclin-dependent kinase 2(CDK2) plays a crucial role in cell cycle regulation and has emerged as a promising therapeutic target in cancer drug development. This study focused on the design,...

Arun Kumar T, A. K. · 0 citations
Open access Oct 2026

Synthesis, antitumor evaluation, and in silico investigation of pyridine-based pyrimidotriazine and triazolopyrimidine derivatives as potential EGFR-targeted anticancer agents

Cancer remains a major global health challenge and one of the leading causes of mortality worldwide. In the present study, a new series of fused nitrogen-containing heterocyclic derivatives was synthesized from a pyridine-based pyrimidinethione key synthon. Hydrazinolysis followed by cyclo-condensation and condensation...

S. K. Ramadan, Ali H. Abdelrahman, M. Hegazy et al. · 0 citations
Open access Oct 2026

Design, Synthesis, and Anticancer Evaluation of Novel Chalcone Derivatives Bearing Piperazine and Morpholine Moieties

Cancer remains one of the leading causes of mortality worldwide, highlighting the need for novel anticancer agents with improved efficacy and selectivity. In this study, a series of chalcone derivatives bearing phenylpiperazine, 2‐fluorophenylpiperazine, and morpholine moieties (1a–g, 2a–g, and 3a–g) were designed, syn...

N. Çalışkan, F. Yılmaz, O. E. Eyupoğlu et al. · 0 citations
Open access Sep 2026

Design, synthesis, and molecular modeling of quinoline-linked diphenylpyrazoles as multitarget EGFR, VEGFR-2, and COX-2 inhibitors with anticancer, anti-inflammatory and apoptosis-inducing properties.

A new series of quinoline-diphenylpyrazole hybrids were rationally designed, synthesized, and biologically evaluated as potential EGFR/VEGFR-2/COX-2 inhibitors, supporting the proposed hybrid design strategy.

Abdelrahman Hamdi, Mohamed R. Elnagar, M. Hussein et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.